John P. Seibyl, MD, is currently Chairman of the Board at the Institute for Neurodegenerative Disorders and Professsor, adjunct at the Yale University School of Medicine. He is also Distinguished Scientist at inviCRO, LLC having recently retired as Managing Director following a merger in 2016 with Molecular Neuroimaging, a company he co-founded in New Haven, Connecticut. Prior to this, Dr. Seibyl was Chief of the Section of Nuclear Medicine and the Director of the Yale PET Center and NeuroSPECT Center within the Yale School of Medicine. He is board-certified in both Psychiatry and Nuclear Medicine, having completed training in both specialties at Yale. Dr. Seibyl has won numerous grants and contracts over the course of his 30-year career in brain imaging. He is currently the Co-PI for the Imaging core of the Parkinson’s Progression Marker Initiative (PPMI) Trial, a large, multicenter, International trial of Parkinson’s disease progression. Active in his community, Dr. Seibyl is a past president of the Greater New York Chapter of the SNMMI and the Brain ImagingCouncil. He was awarded the 2015 Kuhl-Lassen award by SNMMI for his research contributions including development of visual and quantitative analysis for PET imaging in neurodegenerative and neuropsychiatric disorders. He is a frequent reviewer and author for top-tier nuclear imaging journals, and serves on international panels for his work in neurodegenerative disease imaging. Dr. Seibyl is an author on over 300 publications on brain imaging. His work is challenged and enlightened by his own diagnosis with Parkinson’s disease.